-transparent.png){kind=logo}
The antileukemic activity of karminomycin and rubomycin was studied comparatively in parallel experiments with respect to 4 strains of transplantable leukemia, i.e. acute non-differentiated leukemia La, acute lymphoblast leukemia, L-1210 and P-388 and subacute lymphoblast leukemia No. 8 CRIHBT. The doses used were adequate by their toxicity. The tests of the therapeutic effectiveness were: an increase in the life time of the animals treated as compared to the control ones, a decrease in the leukocyte count and the number of the blast cells in the peripheral blood, a decrease in the leukemic infiltration of the organs and tissues of the animals treated. It was shown that karminomycin was more effective in the studied leukemia strains when it was used in the doses with equivalent toxicity. The more pronounced antileukemic activity of karminomycin was especially evident from histological examinations, which showed lower infiltration of the organs and tissues of the mice treated with karminomycin by the leukemic cells as compared to the animals treated with rubomycin.
O K Khanykova, and
G F Vinogorova
June 1978,
Antibiotiki,
O K Khanykova, and
G F Vinogorova
October 1988,
Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
O K Khanykova, and
G F Vinogorova
February 1990,
Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
O K Khanykova, and
G F Vinogorova
July 1979,
Antibiotiki,
O K Khanykova, and
G F Vinogorova
January 1980,
Oncology,
O K Khanykova, and
G F Vinogorova
January 1977,
Antibiotiki,
O K Khanykova, and
G F Vinogorova
January 1978,
Antibiotiki,
O K Khanykova, and
G F Vinogorova
January 1981,
Antibiotiki,
O K Khanykova, and
G F Vinogorova
June 1984,
Antibiotiki,
O K Khanykova, and
G F Vinogorova
May 1981,
Antibiotiki,
